Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2, single-blind, randomized, controlled, multi-center study to evaluate the efficacy and safety of SRM003 (Vascugel) in improving the rate of arteriovenous fistula maturation and use in subjects undergoing surgery for creation of an arteriovenous fistula for hemodialysis access

Next Previous
Trial Profile

A phase 2, single-blind, randomized, controlled, multi-center study to evaluate the efficacy and safety of SRM003 (Vascugel) in improving the rate of arteriovenous fistula maturation and use in subjects undergoing surgery for creation of an arteriovenous fistula for hemodialysis access

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SRM 003 (Primary)
  • Indications Arteriovenous fistula
  • Focus Therapeutic Use
  • Sponsors Shire

Most Recent Events

  • 04 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 08 Sep 2014 Planned End Date changed from 1 Dec 2014 to 1 Apr 2015, as reported by ClinicalTrials.gov
  • 18 Jul 2014 According to a Shire Pharmaceuticals media release, no new patients will be enrolled in this and another phase II trial (700237715), but those currently in the trials will be followed for at least 12 weeks for safety.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top